Anomalies of the genetic complement and its role in C3 Glomerulopathies and development of Hemolithic Uremic Syndrome
Keywords:
genetic complement anomalies, glomerulopathy, active C3
Abstract
Let us remember that C3 glomerulopathy is the product of an abnormal activation in the alternative complement pathway, which leads to an excessive production of active C3 and its degradation products
Downloads
Download data is not yet available.
References
1. Servais A, Noël L, Roumenina L, Le Quintrec M, Ngo S, Dragon-Durey M et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney International. 2012;82(4):454-464.
2. Taborda-MurilloA, Arroyave-SuárezMJ, Arias-RestrepoLF. Glomerulonefritis C3: una nueva categoría de glomerulonefritis con implicaciones etiopatogénicas. Iatreia [Internet]. 29 de diciembre de 2015 [citado 10 de marzo de 2021];28(1): Pág. 24-34. Disponible en:https://revistas.udea.edu.co/index.php/iatreia/article/view/17580
3. Cook H, Pickering M. Histopathology of MPGN and C3 glomerulopathies. Nature Reviews Nephrology. 2015;11(1):14-22.
4. Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C et al. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex–Mediated Membranoproliferative GN. Journal of the American Society of Nephrology. 2017;29(1):283-294.
5. Häffner, K., Michelfelder, S. & Pohl, M. Tratamiento exitoso de la glomerulopatía C3 positiva para C3Nef con terapia de plasma e inmunosupresión. Pediatr Nephrol 30, 1951-1959 (2015). https://doi.org/10.1007/s00467-015-3111-9
2. Taborda-MurilloA, Arroyave-SuárezMJ, Arias-RestrepoLF. Glomerulonefritis C3: una nueva categoría de glomerulonefritis con implicaciones etiopatogénicas. Iatreia [Internet]. 29 de diciembre de 2015 [citado 10 de marzo de 2021];28(1): Pág. 24-34. Disponible en:https://revistas.udea.edu.co/index.php/iatreia/article/view/17580
3. Cook H, Pickering M. Histopathology of MPGN and C3 glomerulopathies. Nature Reviews Nephrology. 2015;11(1):14-22.
4. Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C et al. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex–Mediated Membranoproliferative GN. Journal of the American Society of Nephrology. 2017;29(1):283-294.
5. Häffner, K., Michelfelder, S. & Pohl, M. Tratamiento exitoso de la glomerulopatía C3 positiva para C3Nef con terapia de plasma e inmunosupresión. Pediatr Nephrol 30, 1951-1959 (2015). https://doi.org/10.1007/s00467-015-3111-9
How to Cite
1.
Delgado JET, Lozano CAP, Roncallo LMO, Pérez SJR, Agámez AGL, Gómez MJ Álvarez, Zúñiga RJG, Pérez AMG. Anomalies of the genetic complement and its role in C3 Glomerulopathies and development of Hemolithic Uremic Syndrome. Med. res. chronicles [Internet]. 2021Jul.20 [cited 2024Nov.17];8(4):303-4. Available from: https://medrech.com/index.php/medrech/article/view/516
Section
Editorial Note
